ReviewHuman vaccines2011
Meningococcal glycoconjugate vaccines.
Review in Human vaccines, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 63 citations in OpenAlex.
- Chemoenzymatic Synthesis of Well-Defined α(2,8)- and α(2,9)-Linked Oligosialosides.Angewandte Chemie (International ed. in English) · 2026Article
- Capsular immunity is necessary for protection against some but not all strains of Glaesserella parasuis.Veterinary microbiology · 2025Article
- Testing a Recombinant Form of Tetanus Toxoid as a Carrier Protein for Glycoconjugate Vaccines.Vaccines · 2023Article
- Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial.Lancet regional health. Americas · 2023Article
- Synthetic carbohydrate-based vaccines: challenges and opportunities.Journal of biomedical science · 2020Review
- Meningitis B vaccination: knowledge and attitudes of pediatricians and parents in Greece.Heliyon · 2018Article
- Determination of the binding affinities of Neisseria meningitidis serogroup W capsule polymerase with two nucleotide sugar substrates.BMC research notes · 2018Article
- Challenges and opportunities for meningococcal vaccination in the developing world.Human vaccines & immunotherapeutics · 2018Review
- Review
- Abundance and co-occurrence of extracellular capsules increase environmental breadth: Implications for the emergence of pathogens.PLoS pathogens · 2017Article
- Antibody repertoire profiling with mimotope arrays.Human vaccines & immunotherapeutics · 2017Article
- Global Meningococcal Initiative: guidelines for diagnosis and confirmation of invasive meningococcal disease.Epidemiology and infection · 2016Review
- Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysis.Human vaccines & immunotherapeutics · 2016Article
- How the Knowledge of Interactions between Meningococcus and the Human Immune System Has Been Used to Prepare Effective Neisseria meningitidis Vaccines.Journal of immunology research · 2015Review
- Identification and therapeutic potential of a vitronectin binding region of meningococcal msf.PloS one · 2015Article
- Investigating the candidacy of a lipoteichoic acid-based glycoconjugate as a vaccine to combat Clostridium difficile infection.Glycoconjugate journal · 2013Article
- Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future.Human vaccines & immunotherapeutics · 2013Review
- Article
- Chromatographic analysis of the Escherichia coli polysialic acid capsule.Methods in molecular biology (Clifton, N.J.) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neisseria meningitidis is a major cause of invasive bacterial infections worldwide. For this reason, efforts to control the disease have been directed at optimizing meningococcal vaccines and implementing appropriate vaccination policies. In the past, plain polysaccharide vaccines containing purified capsular polysaccharides A, C, Y and W135 were developed, but failed to protect infants, who are at greatest risk. Experience with the conjugate Haemophilus vaccine suggested that this approach might well empower meningococcal vaccines. Thus, a very efficacious vaccine against serogroup C Neisseria meningitis was optimized and has been widely used in developed nations since 1999. On the basis of epidemiological changes in the circulation of pathogenic serogroups in the United States, a quadrivalent conjugate vaccine against A, C, Y and W135 serogroups (Menactra™) has been developed and was approved by the U.S. FDA (Food and Drug Administration) in 2005. Recently, another tetravalent conjugate meningococcal vaccine (Menveo™) has been licensed and made available in the United States of America and in the European Union. Finally, in response to large epidemics caused by serogroup A meningococcus in Africa, a new, safe, immunogenic and affordable vaccine has been developed. This review highlights the evolution of conjugate meningococcal vaccines in general and discusses how this kind of vaccine can contribute to preventing meningococcal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.